Quantum-Si (NASDAQ:QSI) Given New $1.50 Price Target at Canaccord Genuity Group

Quantum-Si (NASDAQ:QSI) had its price objective cut by Canaccord Genuity Group from $2.00 to $1.50 in a research report released on Monday, Marketbeat reports. They currently have a hold rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quantum-Si in a research report on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Quantum-Si currently has an average rating of “Hold” and a consensus price target of $3.60.

Quantum-Si Price Performance

QSI opened at $1.27 on Monday. Quantum-Si has a twelve month low of $0.95 and a twelve month high of $5.77. The company has a market capitalization of $273.67 million, a price-to-earnings ratio of -1.90 and a beta of 2.97. The firm has a 50-day moving average price of $1.66 and a 200-day moving average price of $1.58.

Quantum-Si (NASDAQ:QSI) last posted its earnings results on Wednesday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.60 million. Quantum-Si had a negative return on equity of 47.90% and a negative net margin of 3,677.97%. On average, sell-side analysts expect that Quantum-Si will post -0.65 earnings per share for the current fiscal year.

Insider Activity at Quantum-Si

In related news, CEO Jeffrey Alan Hawkins sold 23,707 shares of Quantum-Si stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $1.28, for a total value of $30,344.96. Following the transaction, the chief executive officer owned 2,578,018 shares in the company, valued at $3,299,863.04. This trade represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jonathan M. Rothberg sold 26,095 shares of the business’s stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $3.07, for a total value of $80,111.65. Following the completion of the sale, the director owned 1,904,866 shares of the company’s stock, valued at $5,847,938.62. The trade was a 1.35% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 80,356 shares of company stock valued at $149,566. Insiders own 22.95% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Quantum-Si by 19.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 367,444 shares of the company’s stock valued at $441,000 after purchasing an additional 59,423 shares in the last quarter. Deutsche Bank AG boosted its stake in Quantum-Si by 107.4% during the 1st quarter. Deutsche Bank AG now owns 67,522 shares of the company’s stock valued at $81,000 after purchasing an additional 34,962 shares during the last quarter. Invesco Ltd. increased its holdings in Quantum-Si by 177.7% in the 1st quarter. Invesco Ltd. now owns 103,657 shares of the company’s stock worth $124,000 after buying an additional 66,336 shares in the last quarter. Nuveen LLC bought a new position in Quantum-Si during the 1st quarter valued at about $383,000. Finally, Russell Investments Group Ltd. boosted its holdings in Quantum-Si by 322.6% in the first quarter. Russell Investments Group Ltd. now owns 38,257 shares of the company’s stock worth $46,000 after purchasing an additional 29,204 shares during the last quarter. 39.90% of the stock is currently owned by institutional investors.

Trending Headlines about Quantum-Si

Here are the key news stories impacting Quantum-Si this week:

• Positive Sentiment: Launched Version 3 library‑preparation kit and a suite of data‑analysis enhancements — a commercial / product execution update that may help drive sample kit revenue, customer adoption and show progress against commercialization targets. Quantum‑Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements
• Neutral Sentiment: Canaccord cut its price target from $2.00 to $1.50 and moved to a “hold” rating — the new PT still implies upside vs. current levels but reflects reduced near‑term expectations; this is a near‑term sentiment headwind from an institutional analyst. Quantum‑Si price target lowered to $1.50 from $2 at Canaccord
• Negative Sentiment: CEO Jeffrey Hawkins sold 23,707 shares at ~$1.28 (≈$30.3k), reducing his stake ~0.91% — insider selling can be viewed negatively by investors even if proceeds are modest. SEC filing — CEO sale
• Negative Sentiment: CFO Jeffry Keyes sold 8,627 shares at ~$1.28 (≈$11.0k), a ~0.74% reduction in his holding — additional insider sales this session add to selling signal. SEC filing — CFO sale
• Negative Sentiment: Director/insider John Vieceli sold 21,927 shares at ~$1.28 (≈$28.1k), trimming his stake by ~2.66% — multiple insiders selling the same day amplifies concern over near‑term insider conviction. SEC filing — Insider sale

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.